BACKGROUND: Methotrexate remains a valuable option for the treatment of psoriasis. This
report will summarize studies regarding the use of methotrexate since the last guidelines …

Objective Treatment of patients with infliximab, a chimeric monoclonal IgG1 antibody against
tumor necrosis factor, may result in the formation of infliximab‐specific IgG antibodies. This …

Increased effectiveness of pharmacological treatments in early RA has led many to believe
that difficult-to-treat, established RA is a condition of the past. However, there are still plenty …

Objectives. An open study of B‐lymphocyte depletion was undertaken in rheumatoid arthritis
(RA) patients to test the hypothesis that B lymphocytes may be essential to disease …

Abstract Background CT-P13 (Remsima®, Inflectra®) is a biosimilar of the infliximab
reference product (RP; Remicade®). The aim of this study was to compare the 54-week …

Advances in cDNA and monoclonal antibody technology in the 1980s fuelled the discovery
and characterization of the properties of cytokines. It became apparent that because …

Background: Oral glucocorticoids combined with disease-modifying antirheumatic drugs are
beneficial and retard radiologic joint damage in rheumatoid arthritis. Objective: To …

Immunogenicity of adalimumab could impair important treatment outcome parameters in
patients with rheumatoid arthritis (RA). Patients who developed antiadalimumab antibodies …

Background & Aims: We assessed the relationship between antibodies to infliximab (ATI)
and the loss of response postinfliximab, infusion reactions and, in a randomized trial …

Objective: To evaluate the safety of biological treatments for rheumatoid arthritis (RA) using
results from randomised controlled trials (RCT). Methods: The literature was searched to …